Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …

Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …

Background Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody–drug
conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum …

PURPOSE Single-agent chemotherapies have limited activity and considerable toxicity in
patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab …

Antibody–drug conjugates (ADCs) have become a credentialled class of anticancer drugs
for both solid and hematological malignancies, with regulatory approvals mainly as single …

Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …

Mirvetuximab soravtansine (mirvetuximab soravtansine-gynx; Elahere™) is an antibody-
drug conjugate (ADC), which is comprised of a folate receptor α (FRα) directed antibody …

Summary The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on
Clinical Research was held virtually in October, 2021, following published consensus …

Ovarian carcinoma is characterized by heterogeneity at the molecular, cellular and
anatomical levels, both spatially and temporally. This heterogeneity affects response to …

Importance Platinum-based chemotherapy has been the standard of care for ovarian cancer
for the past 3 decades. Although most patients respond to platinum-based treatment …